CD30

CD30, also known as TNFRSF8 (TNF receptor superfamily member 8),^[5] is a cell membrane protein of the tumor necrosis factor receptor family and a tumor marker for anaplastic large cell lymphoma.

TNFRSF8
Available structures PDB Ortholog search: PDBe RCSB List of PDB id codes 1D01
Identifiers
Aliases	TNFRSF8, CD30, D1S166E, Ki-1, tumor necrosis factor receptor superfamily member 8, TNF receptor superfamily member 8
External IDs	OMIM: 153243; MGI: 99908; HomoloGene: 949; GeneCards: TNFRSF8; OMA:TNFRSF8 - orthologs
Gene location (Human) Chr. Chromosome 1 (human)[1] Band 1p36.22 Start 12,063,303 bp[1] End 12,144,207 bp[1]
Gene location (Mouse) Chr. Chromosome 4 (mouse)[2] Band 4 E1|4 78.17 cM Start 144,993,707 bp[2] End 145,041,734 bp[2]
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in granulocyte monocyte testicle blood pancreatic ductal cell decidua subcutaneous adipose tissue periodontal fiber appendix right auricle of heart Top expressed in neural layer of retina blastocyst secondary oocyte embryo zygote morula embryo thymus dentate gyrus of hippocampal formation granule cell primary oocyte More reference expression data BioGPS More reference expression data
Gene ontology Molecular function transmembrane signaling receptor activity tumor necrosis factor-activated receptor activity nerve growth factor binding Cellular component cytoplasm integral component of membrane integral component of plasma membrane extracellular exosome membrane plasma membrane nucleus neuron projection Biological process apoptotic signaling pathway cellular response to mechanical stimulus response to lipopolysaccharide inflammatory response immune response signal transduction negative regulation of cell population proliferation positive regulation of apoptotic process tumor necrosis factor-mediated signaling pathway axon guidance negative regulation of neuron projection development positive regulation of NF-kappaB transcription factor activity Sources:Amigo / QuickGO
Orthologs Species Human Mouse Entrez 943 21941 Ensembl ENSG00000120949 ENSMUSG00000028602 UniProt P28908 Q60846 RefSeq (mRNA) NM_001243 NM_001281430 NM_152942 NM_009401 RefSeq (protein) NP_001234 NP_001268359 NP_033427 Location (UCSC) Chr 1: 12.06 – 12.14 Mb Chr 4: 144.99 – 145.04 Mb PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Function

This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB.^[6] It is a positive regulator of apoptosis,^[7] and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity.^{[citation needed]} Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.^[5]

Clinical significance

CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus a useful marker in distinguishing between these germ cell tumors.^[8] CD30 and CD15 are also expressed on Reed-Sternberg cells typical for Hodgkin's lymphoma.^[9]

Cancer treatment

CD30 is the target of the FDA approved therapeutic brentuximab vedotin (Adcetris). It is approved for use in:

1. Hodgkin lymphoma (HL) (brentuximab vedotin) after failure of autologous stem cell transplant (ASCT)
2. HL in patients who are not ASCT candidates after failure of at least 2 multiagent chemotherapy regimens
3. Systemic anaplastic large cell lymphoma (sALCL) after failure of at least 1 multiagent chemotherapy regimen^[10]
4. Primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy^[11]
5. Various types of CD30-positive T cell lymphomas^[12]

Brentuximab vedotin is also currently being studied in and recommended for treating:

1. Various types of CD30-positive B cell lymphomas^[13]
2. CD30-positive cases of the NK cell lymphoma, extranodal NK/T-cell lymphoma, nasal type^[14]

Interactions

CD30 has been shown to interact with TRAF5,^[6] and TRAF2.^[6][7]